Terms: = Lymphoma AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1 AND Prognosis
1 results:
1. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract] [Full Text] [Related]
